Alivus Life Sciences
897.55
-1.55(-0.17%)
Market Cap₹11,011.26 Cr
PE Ratio20.30
IndustryHealthcare
Company Performance:
1D-0.17%
1M+1.72%
6M-6.12%
1Y-12.73%
5Y+19.91%
View Company Insightsright
More news about Alivus Life Sciences
23Jan 26
Alivus Life Sciences Projects High Single-Digit Revenue Growth for FY26
Alivus Life Sciences management has announced expectations for high single-digit revenue growth in FY26 and the following year during a recent conference call. The projected growth will be driven by two primary factors: expansion in non-GPL segments and the ramp-up of CDMO operations. This strategic approach reflects the company's focus on diversifying revenue streams and strengthening its position in contract development and manufacturing services.
 no imag found
22Jan 26
Alivus Life Sciences Reports 7.14% Growth in Q3 Net Profit to ₹1.50 Billion
Alivus Life Sciences delivered strong Q3 financial results with net profit increasing to ₹1.50 billion from ₹1.40 billion in the same quarter of the previous year, representing a 7.14% year-over-year growth. The results demonstrate the company's consistent operational performance and effective cost management strategies during the reporting period.
 no imag found
21Jan 26
Alivus Life Sciences Allots 55,000 Equity Shares Under ESOP Scheme
Alivus Life Sciences Limited allotted 55,000 equity shares under its Employee Stock Option Scheme 2021 on January 21, 2026, following approval by the Nomination and Remuneration Committee. The allotment increased the company's paid-up share capital from ₹24.54 crores to ₹24.55 crores, with total equity shares rising to 12,27,36,348. The company has informed stock exchanges about this development in compliance with listing requirements.
 no imag found
15Jan 26
Alivus Life Sciences Schedules Q3 FY2025-26 Earnings Call for January 22, 2026
Alivus Life Sciences Limited has scheduled its Q3 FY2025-26 earnings call for January 22, 2026, from 6:00 PM to 7:00 PM IST. The pharmaceutical company has provided comprehensive dial-in details including universal domestic numbers and international toll-free and toll numbers for participants across multiple countries. The earnings call notification was filed under Regulation 30 with both BSE and NSE, with contact persons available for clarifications.
 no imag found
13Nov 25
Alivus Life Sciences Reports Robust Q2 FY26 Results with 16% Revenue Growth
Alivus Life Sciences Limited reported robust Q2 FY26 results with revenue increasing 16% year-on-year to ₹588 crores. EBITDA grew 35.70% to ₹194 crores, with margin expanding to 33%. The non-GPL business grew 39.70%, driving overall growth. Gross margin improved to 57.70%, up 210 bps. The company remains debt-free with ₹653 crores in cash and equivalents. Management reaffirmed high single-digit revenue growth guidance for FY26 and expects to sustain margins around 30%.
 no imag found
06Nov 25
Alivus Life Sciences Reports Strong Q2 Growth, Driven by Non-GPL Business
Alivus Life Sciences Limited reported robust Q2 financial results with revenue from operations at ₹5,880.00 crore, up 16% YoY. EBITDA increased by 35.7% to ₹1,939.00 crore, with margins expanding to 33%. PAT grew by 36.5% to ₹1,301.00 crore. The non-GPL business, contributing 75.6% of total revenue, grew by 39.7% YoY. Regulated markets accounted for 81% of revenue, with chronic therapies contributing 69%. The company generated ₹1,477.00 crore in free cash flow in H1 and had ₹6,526.00 crore in cash and equivalents as of September 30. Expansion plans are underway at Solapur, Ankleshwar, and Dahej plants.
 no imag found
06Nov 25
Alivus Life Sciences Reports Robust Q2 FY26 Performance with 16% Revenue Growth and Margin Expansion
Alivus Life Sciences Limited announced robust Q2 FY26 financial results. Revenue increased 16% YoY to ₹5,880.00 Mn, driven by 39.7% growth in non-GPL business. EBITDA grew 35.7% to ₹1,939.00 Mn with margin expanding to 33.0%. PAT rose 36.5% to ₹1,301.00 Mn. The company maintained strong performance across key markets and expects continued growth in H2 FY26. Alivus remains debt-free with ₹653.00 crores in cash and cash equivalents.
 no imag found
20Oct 25
Alivus Life Sciences Faces Rs 50 Lakh Environmental Penalty Following Plant Incident
Alivus Life Sciences Limited has been issued a notice by the Gujarat Pollution Control Board (GPCB) imposing an interim Environment Damage Compensation of Rs 50 lakhs following a flash fire incident at their Ankleshwar Plant on September 30, 2025. The company is required to deposit Rs 29 lakhs immediately and provide a bank guarantee of Rs 10 lakhs. Alivus Life Sciences states that the incident and penalty are not expected to materially impact their financial position or operations. The company is considering appealing the order.
 no imag found
26Jul 25
Alivus Life Sciences Secures USFDA's No Action Indicated Status for Gujarat API Facility
Alivus Life Sciences Limited has obtained an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) classification from the USFDA for its API manufacturing facility in Gujarat. The inspection was conducted from May 26 to May 30, 2025. The NAI classification indicates that the facility met regulatory standards and no objectionable conditions were observed during the inspection.
 no imag found
26Jul 25
Alivus Life Sciences Receives USFDA's No Action Indicated Status for Gujarat API Facility
Alivus Life Sciences Limited's API manufacturing facility in Dahej, Gujarat, received an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) classification from the USFDA. The inspection took place from May 26 to May 30. This positive outcome indicates that the facility met all regulatory standards, requiring no corrective actions. The company, formerly known as Glenmark Life Sciences Limited, officially informed the stock exchanges on July 26, in compliance with SEBI regulations.
 no imag found
30May 25
Alivus Life Sciences Achieves Flawless USFDA Inspection at Dahej API Facility
Alivus Life Sciences' Active Pharmaceutical Ingredient (API) facility in Dahej, Gujarat, successfully completed a United States Food and Drug Administration (USFDA) inspection with zero Form 483 observations. This outcome validates the facility's adherence to Good Manufacturing Practices (GMP) and demonstrates the company's commitment to quality and regulatory compliance. The successful inspection potentially strengthens Alivus Life Sciences' position in the global pharmaceutical market, particularly for products destined for the U.S. market, and builds confidence among regulators, partners, and customers.
 no imag found
15May 25
Alivus Life Sciences Reports Strong Q4 Results, Recommends Dividend
Alivus Life Sciences announced robust Q4 financial results with significant year-over-year growth. Revenue increased by 21.3% to ₹6.50 billion, EBITDA grew by 40.4% to ₹1.98 billion, and net profit rose by 42.9% to ₹1.40 billion. The company's EBITDA margin expanded by 420 basis points to 30.56%. Additionally, Alivus recommended a dividend of ₹5 per equity share.
 no imag found
04Apr 25
Alivus Life Sciences Receives USFDA EIR with VAI Status for Ankleshwar Facility
Alivus Life Sciences Limited has received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its API manufacturing facility in Ankleshwar, Gujarat. The inspection was conducted from January 27-31, 2025. The VAI status allows the company to continue operations while addressing minor issues, indicating substantial compliance with good manufacturing practices.
 no imag found
03Apr 25
Alivus Life Sciences to Acquire 9.21% Stake in Torrent Urja 19 for ₹156 Crore
Alivus Life Sciences Limited is acquiring a 9.21% stake in Torrent Urja 19 Private Limited for ₹156 crore. This strategic investment aims to increase renewable power usage in Alivus' operations, aligning with its goal to become carbon neutral by 2030. The acquisition will also help Alivus comply with Indian electricity laws for captive power users. The transaction involves equity shares at face value and is expected to complete within 6 months. Alivus has signed a Share Purchase cum Subscription Shareholders' Agreement and a Power Supply Agreement with Torrent Urja 19.
 no imag found
Alivus Life Sciences
897.55
-1.55
(-0.17%)
1 Year Returns:-12.73%
Industry Peers
Sun Pharmaceutical
1,722.80
(-0.09%)
Divis Laboratories
6,323.00
(+0.63%)
Torrent Pharmaceuticals
4,236.10
(+0.60%)
Cipla
1,335.20
(-1.08%)
Dr Reddys Laboratories
1,287.00
(+0.52%)
Lupin
2,246.90
(+0.91%)
Zydus Life Science
906.95
(-0.34%)
Mankind Pharma
2,047.10
(-1.37%)
Aurobindo Pharma
1,191.60
(+2.76%)
Alkem Laboratories
5,405.50
(-1.07%)